Benzinga | Apr 12, 2021 08:11AM EDT

Ardelyx To Present Data From NORMALIZE Phase 4 Trial At ISN World Congress of Nephrology 2021 Apr. 16-19

Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it will present a poster highlighting data from NORMALIZE, an ongoing Phase 4 trial designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve normal serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis at the ISN World Congress of Nephrology 2021, which will take place virtually April 16-19, 2021.

Details on Ardelyx's poster:

Abstract Title: A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Achieve Normal Serum Phosphorus in Patients with CKD on Dialysis (NORMALIZE)

Authors: David P. Rosenbaum, Yang Yang, Arnold Silva, German T. Hernandez, Geoffrey A. Block

Abstract number: WCN21-0374

For more information on these and other abstracts, please visit the ISN World Congress of Nephrology 2021 website.